ArticleHead and neck pathology2025
Palisading Adenocarcinoma: Several New Inherited Cases in Six Patients of a Familial Cohort.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent developments in salivary gland pathology after the WHO 2024 classification: new developments in existing entities and evolving new entities.Virchows Archiv : an international journal of pathology · 2026Review
- Palisading adenocarcinoma. State of the art and first case report in the parotid gland of a 44-year-old woman.Pathologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe past two decades have seen the introduction of several new variants of established salivary gland tumors, along with occasional, entirely novel entities. Palisading adenocarcinoma was described in 2023 with a handful of subsequent additional case reports. We encountered several seemingly inherited cases of palisading adenocarcinoma in a familial cohort.
methodsWithin the affected family, all available archival surgical pathology and cytopathology material was retrieved and reviewed. Clinical history was obtained through chart review. Whole-exome sequencing was performed on two cases.
resultsSix patients were affected by palisading adenocarcinoma. The patients ranged from 33 to 72 years (mean, 52.3 years) and were all women. Each patient had ≥ 2 documented tumors, and the locations of involvement were: parotid gland (n = 7), floor of mouth (n = 4), submandibular gland (n = 3), neck (n = 2), orbit (n = 1), and maxilla (n = 1). Although not every clinically documented case was available for histologic review, all cases that were evaluated demonstrated the features described for palisading adenocarcinoma, including two cell populations of ducts with polygonal neuroendocrine-like cells arranged as trabeculae with palisading, and strong positivity for CD56 but not other neuroendocrine markers. Whole-exome sequencing did not reveal any recurrent alterations.
conclusionWe present 18 new cases of palisading adenocarcinoma, including 12 documented pathologically, occurring in women in the same family. This series doubles the published experience of this emerging tumor. While most of the previously published features of palisading adenocarcinoma were confirmed (female predominance, Asian population, sublingual and submandibular location), this series expands what is known about this neoplasm with novel sites (with parotid gland being most common) and apparent inheritability, a very rare characteristic among salivary gland neoplasms. While we were unable to uncover its molecular driver, this potential inheritability is a clue that may allow for future studies to unravel the genetics of palisading adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.